Roxadustat

Erythropoietin Products · Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor 

Indications

Symptomatic anaemia associated with chronic kidney disease (CKD).

Dosage

ORAL: Adults: 3 times/wk and not on consecutive days. The dose should be individualized and maintain target Hb levels of 10-12 gm/dL. See literature. Roxadustat treatment should not be continued beyond 24 weeks of therapy if a clinically meaningful increase in Hb levels is not achieved.

Adverse Effects

Hyperkalaemia, hypertension, vascular access thrombosis (in dialysis patients), GI upset, peripheral oedema, sepsis, insomnia, seizures, headache, DVT. Reports of PE.

Risk Factor (Pregnancy/Lactation)

Contraindications: Severe hepatic impairment. Peanut or soya allergy. Pregnancy; ensure contraception during and for =1 week after end of treatment. Lactation. Precautions: Monitor Hb. Moderate hepatic impairment. Risk factors for VTE. Epilepsy, history of or predisposition to seizures. In case of inadequate response, investigate potential causes and consider reticulocyte count.

Interactions

CYP2C8 inhibitors (eg, gemfibrozil) or inducers (eg, rifampicin). UT1A9 inhibitors (eg, probenecid). Phosphate binders, products containing calcium, iron, magnesium or aluminium. Statins, other substrates of BCRP or OATP1B1. Erythropoiesis-stimulating agents.

Advice to Patient

Take with or without meals. Roxadustat has minor influence on the ability to drive and use machines. Seizures have been reported during treatment. Caution should be exercised when driving or operating machines.

Pharmacokinetics

Metabolism: Hepatic. Half-life elimination: 15 hrs in patients with CKD. Time to peak, plasma: 2 hrs.

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.